Jim Simons Biomea Fusion, Inc. Transaction History

Renaissance Technologies LLC

$62.3 Billion
Q1 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 278,119 shares of BMEA stock, worth $400,491. This represents 0.0% of its overall portfolio holdings.

Number of Shares

278,119

Previous 343,732 19.09%

Holding current value

$400,491

Previous $1.33 Million 55.59%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$2.13 - $4.48 $139,755 - $293,946	-65,613 Reduced 19.09%	278,119 $592,000
Q4 2024 Feb 13, 2025	BUY	$3.88 - $12.41 $1.01 Million - $3.24 Million	261,432 Added 317.66%	343,732 $1.33 Million
Q3 2024 Nov 13, 2024	SELL	$4.23 - $10.1 $1.04 Million - $2.49 Million	-246,806 Reduced 74.99%	82,300 $831,000
Q2 2024 Aug 09, 2024	BUY	$4.14 - $15.3 $1.36 Million - $5.04 Million	329,106 New	329,106 $1.48 Million
Q1 2023 May 12, 2023	BUY	$6.8 - $32.35 $114,240 - $543,480	16,800 Added 26.67%	79,800 $2.48 Million
Q4 2022 Feb 13, 2023	BUY	$6.3 - $11.6 $7,560 - $13,920	1,200 Added 1.94%	63,000 $531,000
Q3 2022 Nov 14, 2022	BUY	$9.51 - $13.61 $120,777 - $172,847	12,700 Added 25.87%	61,800 $604,000
Q2 2022 Aug 12, 2022	BUY	$3.0 - $12.03 $95,400 - $382,554	31,800 Added 183.82%	49,100 $588,000
Q1 2022 May 13, 2022	BUY	$4.39 - $9.03 $877 - $1,805	200 Added 1.17%	17,300 $77,000
Q4 2021 Feb 11, 2022	BUY	$7.22 - $12.72 $123,462 - $217,512	17,100 New	17,100 $127,000

Others Institutions Holding BMEA

# of Institutions

109

Shares Held

16.1M

Call Options Held

229K

Put Options Held

354K

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $42.2M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account